NASDAQ:IMGN ImmunoGen - IMGN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.55 -0.22 (-4.61%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$4.55▼$4.8050-Day Range$4.14▼$5.4752-Week Range$3.10▼$6.63Volume1.99 million shsAverage Volume3.08 million shsMarket Capitalization$1.00 billionP/E RatioN/ADividend YieldN/APrice Target$12.11 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability ImmunoGen MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside166.2% Upside$12.11 Price TargetShort InterestBearish8.13% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.32Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.13 out of 5 starsMedical Sector436th out of 1,026 stocksPharmaceutical Preparations Industry206th out of 504 stocks 3.3 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.11, ImmunoGen has a forecasted upside of 166.2% from its current price of $4.55.Amount of Analyst CoverageImmunoGen has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.13% of the outstanding shares of ImmunoGen have been sold short.Short Interest Ratio / Days to CoverImmunoGen has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in ImmunoGen has recently decreased by 0.50%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 73.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.85. Previous Next 1.8 News and Social Media Coverage News SentimentImmunoGen has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ImmunoGen this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for IMGN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ImmunoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.34% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions89.13% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow in the coming year, from ($0.94) to ($0.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -5.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ImmunoGen (NASDAQ:IMGN) StockImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.Read More Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Stock News HeadlinesJanuary 3, 2023 | finance.yahoo.comNeed To Know: The Consensus Just Cut Its ImmunoGen, Inc. (NASDAQ:IMGN) Estimates For 2023December 30, 2022 | finance.yahoo.comCompany News for Dec 30, 2022February 9, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.December 28, 2022 | finance.yahoo.comImmunoGen's Newly Approved Ovarian Cancer Drug Listed As Preferred RegimeDecember 27, 2022 | finance.yahoo.comImmunoGen Announces Webcast of Presentation and Q&A at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 15, 2022 | finance.yahoo.comWill ImmunoGen (NASDAQ:IMGN) Spend Its Cash Wisely?December 10, 2022 | finance.yahoo.comImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASHNovember 17, 2022 | finance.yahoo.comIndustry Analysts Just Upgraded Their ImmunoGen, Inc. (NASDAQ:IMGN) Revenue Forecasts By 23%February 9, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.November 16, 2022 | finance.yahoo.comAfter FDA Approval For Ovarian Cancer Drug, ImmunoGen Becomes Top Pick For This AnalystNovember 15, 2022 | finance.yahoo.comImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer DrugNovember 15, 2022 | finance.yahoo.comFDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian CancerNovember 9, 2022 | finance.yahoo.comImmunoGen Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | finance.yahoo.comImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View UpNovember 3, 2022 | finance.yahoo.comShould You Buy ImmunoGen (IMGN) Ahead of Earnings?October 28, 2022 | finance.yahoo.comImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy?October 14, 2022 | bizjournals.comForm D Friday: CXL Ophthalmics $32M, i2o Therapeutics $33.5M, Phoenicis Therapeutics $9.9M - The Business JournalsOctober 13, 2022 | finance.yahoo.comINOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis - Yahoo FinanceOctober 5, 2022 | businesswire.comGlobal Drug Conjugates Market Report (2022 to 2027) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts - ResearchAndMarkets.com - Business WireOctober 4, 2022 | nasdaq.comImmunoGen (IMGN) Shares Cross Above 200 DMA - NasdaqSeptember 29, 2022 | businesswire.comImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS - Business WireSeptember 23, 2022 | reuters.comIMGN.OQ - ImmunoGen, Inc. | Stock Price & Latest News | ReutersSeptember 14, 2022 | businesswire.comImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference - Business WireSeptember 12, 2022 | finance.yahoo.comNeoImmuneTech's NT-I7 Creates a More Immunogenic Tumor Microenvironment when Associated with Pembrolizumab - Yahoo FinanceSeptember 11, 2022 | benzinga.comImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMOSeptember 7, 2022 | nasdaq.comImmunoGen Breaks Below 200-Day Moving Average - Notable for IMGNSeptember 2, 2022 | nasdaq.comWhy Is Pacira (PCRX) Down 9.2% Since Last Earnings Report? - NasdaqSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address IMGN Company Calendar Last Earnings10/29/2021Today2/09/2023Next Earnings (Estimated)2/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees106Year Founded1981Price Target and Rating Average Stock Price Forecast$12.11 High Stock Price Forecast$22.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+166.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,300,000.00 Net Margins-210.33% Pretax Margin-210.33% Return on Equity-75.89% Return on Assets-44.97% Debt Debt-to-Equity RatioN/A Current Ratio3.19 Quick Ratio3.19 Sales & Book Value Annual Sales$95.61 million Price / Sales10.51 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book2.83Miscellaneous Outstanding Shares220,751,000Free Float213,378,000Market Cap$1.00 billion OptionableOptionable Beta0.85 Social Links Key ExecutivesMark Joseph EnyedyPresident, Chief Executive Officer & DirectorRenee LentiniVP-Finance, Chief Financial & Accounting OfficerAnna BerkenblitChief Medical Officer & Senior Vice PresidentThomas RyllSenior Vice President-Technical OperationsMichael J. VasconcellesEVP-Research, Development & Medical AffairsKey CompetitorsOPKO HealthNASDAQ:OPKInnovivaNASDAQ:INVALigand PharmaceuticalsNASDAQ:LGNDIntercept PharmaceuticalsNASDAQ:ICPTGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsSwiss National BankBought 8,900 shares on 2/8/2023Ownership: 0.217%Arizona State Retirement SystemBought 2,115 shares on 2/8/2023Ownership: 0.025%Russell Investments Group Ltd.Bought 37,300 shares on 2/8/2023Ownership: 0.024%Cambridge Investment Research Advisors Inc.Sold 2,698 shares on 2/8/2023Ownership: 0.023%Raymond James Financial Services Advisors Inc.Bought 29,261 shares on 2/8/2023Ownership: 0.023%View All Institutional Transactions IMGN Stock - Frequently Asked Questions Should I buy or sell ImmunoGen stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunoGen in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMGN shares. View IMGN analyst ratings or view top-rated stocks. What is ImmunoGen's stock price forecast for 2023? 7 brokerages have issued 12-month price targets for ImmunoGen's shares. Their IMGN share price forecasts range from $5.00 to $22.00. On average, they predict the company's share price to reach $12.11 in the next year. This suggests a possible upside of 166.2% from the stock's current price. View analysts price targets for IMGN or view top-rated stocks among Wall Street analysts. How have IMGN shares performed in 2023? ImmunoGen's stock was trading at $4.96 at the beginning of 2023. Since then, IMGN stock has decreased by 8.3% and is now trading at $4.55. View the best growth stocks for 2023 here. When is ImmunoGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023. View our IMGN earnings forecast. How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) announced its quarterly earnings data on Friday, October, 29th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.01. The biotechnology company had revenue of $9.20 million for the quarter, compared to analysts' expectations of $19.03 million. ImmunoGen had a negative trailing twelve-month return on equity of 75.89% and a negative net margin of 210.33%. ImmunoGen's revenue was down 49.5% compared to the same quarter last year. During the same period last year, the business posted ($0.13) EPS. What guidance has ImmunoGen issued on next quarter's earnings? ImmunoGen issued an update on its FY 2022 earnings guidance on Friday, November, 18th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$90.00 million, compared to the consensus revenue estimate of $80.22 million. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some companies that other ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV), Gilead Sciences (GILD), OPKO Health (OPK), AT&T (T) and Dynavax Technologies (DVAX). What is ImmunoGen's stock symbol? ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN." Who are ImmunoGen's major shareholders? ImmunoGen's stock is owned by many different institutional and retail investors. Top institutional investors include Pinnacle Associates Ltd. (0.60%), Pinnacle Associates Ltd. (0.60%), UBS Group AG (0.43%), Fisher Asset Management LLC (0.39%), Swiss National Bank (0.22%) and Hennion & Walsh Asset Management Inc. (0.21%). Insiders that own company stock include Craig Barrows, David G Foster, Mark J Enyedy and Thomas Ryll. View institutional ownership trends. How do I buy shares of ImmunoGen? Shares of IMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ImmunoGen's stock price today? One share of IMGN stock can currently be purchased for approximately $4.55. How much money does ImmunoGen make? ImmunoGen (NASDAQ:IMGN) has a market capitalization of $1.00 billion and generates $69.86 million in revenue each year. The biotechnology company earns $-139,300,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis. How many employees does ImmunoGen have? The company employs 106 workers across the globe. Does ImmunoGen have any subsidiaries? The following companies are subsidiares of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp..Read More How can I contact ImmunoGen? ImmunoGen's mailing address is 830 WINTER ST, WALTHAM MA, 02451. The official website for the company is www.immunogen.com. The biotechnology company can be reached via phone at (781) 895-0600, via email at courtney.okonek@immunogen.com, or via fax at 781-895-0611. This page (NASDAQ:IMGN) was last updated on 2/9/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.